> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# RM Pharma Gains Low-Dose HemiClor Approval
- URL: https://www.fdaweb.com/rm-pharma-gains-low-dose-hemiclor-approval/
- Published: 2025-05-06T12:00:00.000Z
- Updated: 2026-09-14T15:11:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159127

FDA has approved an RM Pharma 505(b)(2) for HemiClor (12.5 mg chlorthalidone) tablets for treating hypertension in adults. Chlorthalidone, a thiazide-like diuretic, has been approved and marketed over several decades, and until now, only higher-dose chlorthalidone tablets (25 mg and 50 mg) have been available in the U.S., according to the company.

The new low-dose option is intended to help clinicians better individualize therapy and potentially reduce the risk of dose-related side effects. “As noted in the approved prescribing information, metabolic adverse effects such as hypokalemia and hyperuricemia are dose-related; thus, a lower starting dose may help mitigate these risks when initiating treatment,” the company says. Studies have demonstrated that “stepped-care treatment strategies — which often began with 12.5 mg of chlorthalidone — were effective in reducing the risk of cardiovascular events,” it adds.